What is Ardelyx's product sales, net — total revenues?

Ardelyx (ARDX) reported product sales, net — total revenues of $118.13M in Q2 2026.

How has Ardelyx's product sales, net — total revenues changed year-over-year?

Ardelyx's product sales, net — total revenues increased by 31.1% year-over-year, from $90.08M to $118.13M.

What does product sales, net — total revenues mean?

This metric represents the total net revenue generated from the sale of pharmaceutical products after accounting for returns, allowances, and rebates. It serves as a primary indicator of market adoption and commercial success for the company's therapeutic portfolio. Tracking this figure allows investors to assess the growth trajectory and revenue-generating capacity of the company's core commercial assets.

Ardelyx (ARDX) Product sales, net — Total revenues

Screener

Other product segments

IBSRELA

$86.24M+32.6%

XPHOZAH

$31.89M+27.4%

Product supply revenue

$1.98M-68.1%

Non-cash royalty revenue related to the sale of future royalties

$676K-51.0%

Licensing revenue

$96K+380%

Similar metrics at other companies

NBIXNet product sales — Total revenues

$811M+43.9%

SUPNNet product sales — Total revenues

$150.75M+6.2%

RYTMProduct revenue, net — Total revenues

$60.11M+59.4%

GERNProduct revenue, net — Total revenues

$57.47M+17.3%

KTOSProduct sales — Total revenues

$237M+18.4%

AMGNProduct sales — Total revenues

$9.54B+8.7%

Other financials

Income statement

See full

Revenue$120.9M+23.8%

Gross profit$115.1M+35.0%

Operating income-$12.4M+13.7%

Net income-$16.7M+12.4%

EPS (diluted)-$0.07+12.5%

Balance sheet

See full

Cash & equivalents$97.2M+7.9%

Total debt$256.2M+24.0%

Total equity$149.0M+6.8%

Total assets$575.9M+23.4%

Cash flow

See full

Operating cash flow-$6.4M+74.7%

CapEx$13.0K-98.0%

Free cash flow-$6.4M+75.3%

Valuation

See full

Market cap$1.2B-4.0%

Enterprise value$1.36B-0.6%

P/S2.7×-0.6×

Profitability

See full

Gross margin94.4%+9.6pp

Operating margin-25.4%—

Net margin-12.4%—

FCF margin-40.9%—

Returns & leverage

See full

Return on equity-38.6%—

Debt / equity1.7×+0.2×

Current ratio3.3×-1.0×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Ardelyx’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 4:12 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001437402-26-000044

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
Revenues
Product sales, net	$118,129	$90,077	$211,502	$157,891
Product supply revenue	1,976	6,185	2,330	6,439
Licensing revenue	96	20	147	5,040
Non-cash royalty revenue related to the sale of future royalties	676	1,380	1,371	2,406
Total revenues	120,877	97,662	215,350	171,776
Costs and operating expenses
Cost of sales	5,759	12,403	10,570	24,706

Item 1. Financial Statements (Unaudited)

FAQ

What is Ardelyx's product sales, net — total revenues?: Ardelyx (ARDX) reported product sales, net — total revenues of $118.13M in Q2 2026.
How has Ardelyx's product sales, net — total revenues changed year-over-year?: Ardelyx's product sales, net — total revenues increased by 31.1% year-over-year, from $90.08M to $118.13M.
What does product sales, net — total revenues mean?: This metric represents the total net revenue generated from the sale of pharmaceutical products after accounting for returns, allowances, and rebates. It serves as a primary indicator of market adoption and commercial success for the company's therapeutic portfolio. Tracking this figure allows investors to assess the growth trajectory and revenue-generating capacity of the company's core commercial assets.